Andrea Harkin
8PUBLICATIONS
105CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Jan 09, 2026
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.Timothy Iveson, Mark P Saunders, Caroline Kelly
|Mar 28, 2024
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.Claire Gallois, Qian Shi, Levi D Pederson
|Mar 14, 2024
Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.Enric Domingo, Caroline Kelly, Jennifer Hay
|Nov 09, 2021
Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.Elisa Fontana, Jeff Meyers, Alberto Sobrero
|Jun 23, 2021
Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer.Prunella Blinman, Andrew Martin, Michael Jefford
|Jan 13, 2021
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer.Timothy J Iveson, Alberto F Sobrero, Takayuki Yoshino
Pageof 2
Frequent Collaborators
7 joint publications
Timothy J Iveson
3 joint publications
Niels Henrik Hollander
3 joint publications
Qian Shi
3 joint publications
Ioannis Boukovinas
3 joint publications
Takayuki Yoshino
3 joint publications
Eiji Oki
3 joint publications
Sara Lonardi
3 joint publications
James Paul
2 joint publications
Louise Medley
2 joint publications
Sarah Pearson
